vs

Side-by-side financial comparison of ADDENTAX GROUP CORP. (ATXG) and INVO Fertility, Inc. (IVF). Click either name above to swap in a different company.

INVO Fertility, Inc. is the larger business by last-quarter revenue ($1.8M vs $975.8K, roughly 1.8× ADDENTAX GROUP CORP.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -430.0%, a 279.5% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs -7.9%). ADDENTAX GROUP CORP. produced more free cash flow last quarter ($-147.7K vs $-1.8M). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs -13.3%).

Addentax Group Corp designs, manufactures and distributes functional workwear, protective clothing and customized uniforms. It also provides integrated apparel supply chain solutions for corporate, industrial and apparel brand clients across North America, Europe and the Asia-Pacific region.

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

ATXG vs IVF — Head-to-Head

Bigger by revenue
IVF
IVF
1.8× larger
IVF
$1.8M
$975.8K
ATXG
Growing faster (revenue YoY)
IVF
IVF
+30.5% gap
IVF
22.6%
-7.9%
ATXG
Higher net margin
IVF
IVF
279.5% more per $
IVF
-150.5%
-430.0%
ATXG
More free cash flow
ATXG
ATXG
$1.6M more FCF
ATXG
$-147.7K
$-1.8M
IVF
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
-13.3%
ATXG

Income Statement — Q3 FY2026 vs Q3 FY2025

Metric
ATXG
ATXG
IVF
IVF
Revenue
$975.8K
$1.8M
Net Profit
$-4.2M
$-2.6M
Gross Margin
30.2%
Operating Margin
-7.0%
-93.1%
Net Margin
-430.0%
-150.5%
Revenue YoY
-7.9%
22.6%
Net Profit YoY
-286.5%
-62.2%
EPS (diluted)
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATXG
ATXG
IVF
IVF
Q4 25
$975.8K
Q3 25
$820.7K
$1.8M
Q2 25
$981.0K
$1.9M
Q1 25
$1.4M
$1.6M
Q4 24
$864.9K
$1.7M
Q3 24
$1.1M
$1.4M
Q2 24
$851.0K
$1.8M
Q1 24
$1.3M
$1.6M
Net Profit
ATXG
ATXG
IVF
IVF
Q4 25
$-4.2M
Q3 25
$-102.8K
$-2.6M
Q2 25
$-392.4K
$-5.3M
Q1 25
$-2.1M
$-17.4M
Q4 24
$-1.1M
$-3.6M
Q3 24
$-721.5K
$-1.6M
Q2 24
$-1.2M
$-2.2M
Q1 24
$864.6K
$-1.6M
Gross Margin
ATXG
ATXG
IVF
IVF
Q4 25
30.2%
Q3 25
27.4%
Q2 25
0.6%
Q1 25
-17.0%
35.2%
Q4 24
22.0%
41.4%
Q3 24
42.3%
31.0%
Q2 24
23.8%
53.1%
Q1 24
24.1%
45.3%
Operating Margin
ATXG
ATXG
IVF
IVF
Q4 25
-7.0%
Q3 25
-54.8%
-93.1%
Q2 25
-63.9%
-160.4%
Q1 25
-82.9%
-1042.1%
Q4 24
-17.3%
-202.0%
Q3 24
-3.7%
-90.7%
Q2 24
-59.3%
-100.9%
Q1 24
-8.9%
-95.7%
Net Margin
ATXG
ATXG
IVF
IVF
Q4 25
-430.0%
Q3 25
-12.5%
-150.5%
Q2 25
-40.0%
-283.6%
Q1 25
-152.8%
-1060.1%
Q4 24
-125.5%
-211.3%
Q3 24
-64.8%
-113.8%
Q2 24
-143.5%
-122.2%
Q1 24
66.6%
-101.3%
EPS (diluted)
ATXG
ATXG
IVF
IVF
Q4 25
Q3 25
$-0.77
Q2 25
$-0.06
$-13.30
Q1 25
$-0.28
$-12.53
Q4 24
$-0.19
$14.86
Q3 24
$-0.13
$-15.11
Q2 24
$-0.25
$-22.39
Q1 24
$0.41
$-7.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATXG
ATXG
IVF
IVF
Cash + ST InvestmentsLiquidity on hand
$238.5K
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$21.6M
$5.8M
Total Assets
$28.2M
$18.8M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATXG
ATXG
IVF
IVF
Q4 25
$238.5K
Q3 25
$445.7K
Q2 25
$490.7K
Q1 25
$325.0K
Q4 24
$480.1K
Q3 24
$810.5K
Q2 24
$904.2K
Q1 24
$816.2K
Total Debt
ATXG
ATXG
IVF
IVF
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ATXG
ATXG
IVF
IVF
Q4 25
$21.6M
Q3 25
$25.9M
$5.8M
Q2 25
$25.2M
$2.6M
Q1 25
$21.7M
$3.3M
Q4 24
$23.8M
$12.7M
Q3 24
$24.8M
$-23.3K
Q2 24
$25.5M
$1.4M
Q1 24
$26.0M
$10.2K
Total Assets
ATXG
ATXG
IVF
IVF
Q4 25
$28.2M
Q3 25
$28.2M
$18.8M
Q2 25
$49.0M
$19.3M
Q1 25
$49.2M
$31.7M
Q4 24
$49.6M
$46.4M
Q3 24
$50.6M
$17.0M
Q2 24
$52.0M
$17.8M
Q1 24
$52.3M
$17.3M
Debt / Equity
ATXG
ATXG
IVF
IVF
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATXG
ATXG
IVF
IVF
Operating Cash FlowLast quarter
$-114.9K
$-1.8M
Free Cash FlowOCF − Capex
$-147.7K
$-1.8M
FCF MarginFCF / Revenue
-15.1%
-101.6%
Capex IntensityCapex / Revenue
3.4%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-1.3M
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATXG
ATXG
IVF
IVF
Q4 25
$-114.9K
Q3 25
$-661.4K
$-1.8M
Q2 25
$-306.1K
$-1.7M
Q1 25
$13.6K
$-3.5M
Q4 24
$273.4K
$-617.4K
Q3 24
$722.2K
$-640.8K
Q2 24
$-193.2K
$-1.5M
Q1 24
$1.1M
$-260.6K
Free Cash Flow
ATXG
ATXG
IVF
IVF
Q4 25
$-147.7K
Q3 25
$-700.0K
$-1.8M
Q2 25
$-383.9K
$-1.7M
Q1 25
$-38.5K
$-3.6M
Q4 24
$235.3K
$-696.3K
Q3 24
$642.1K
Q2 24
$-220.5K
$-1.5M
Q1 24
$-310.3K
FCF Margin
ATXG
ATXG
IVF
IVF
Q4 25
-15.1%
Q3 25
-85.3%
-101.6%
Q2 25
-39.1%
-92.6%
Q1 25
-2.8%
-216.9%
Q4 24
27.2%
-40.6%
Q3 24
57.7%
Q2 24
-25.9%
-82.3%
Q1 24
-19.7%
Capex Intensity
ATXG
ATXG
IVF
IVF
Q4 25
3.4%
Q3 25
4.7%
0.5%
Q2 25
7.9%
0.5%
Q1 25
3.9%
0.9%
Q4 24
4.4%
4.6%
Q3 24
7.2%
0.0%
Q2 24
3.2%
3.0%
Q1 24
3.2%
Cash Conversion
ATXG
ATXG
IVF
IVF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
1.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons